<DOC>
	<DOCNO>NCT01490723</DOCNO>
	<brief_summary>The goal clinical research study learn add Zevalin ( ibritumomab tiuxetan ) low-intensity chemotherapy ( combination rituximab , bendamustine , fludarabine ) , follow allogeneic stem cell transplant , help control lymphoma . The safety combination also study . Two ( 2 ) form ibritumomab tiuxetan use study . 90Y-ibritumomab tiuxetan design attach lymphoma cell destroy cell use radioactive particle attach . 111In-ibritumomab tiuxetan like 90Y- ibritumomab tiuxetan , radioactive particle attach kill lymphoma cell . The radioactive particle make drug able see inside body . It use study predict fast study drug travel body long drug stay body . Rituximab design attach lymphoma cell , may cause die . Bendamustine design damage destroy DNA ( genetic material ) cancer cell . Fludarabine design make cancer cell less able repair damage DNA . This may increase likelihood cell die .</brief_summary>
	<brief_title>Zevalin-Containing Nonmyeloablative Conditioning Stem Cell Transplantation ( SCT )</brief_title>
	<detailed_description>Study Drug Administration Procedures : The chemotherapy , drug study , stem cell transplant give vein central venous catheter ( CVC ) . A central venous catheter sterile flexible tube place large vein local anesthesia remain body treatment . Your doctor explain procedure detail , require sign separate consent form . Blood sample also draw CVC . On Days -22 ( 22 day receive stem cell transplant ) , receive rituximab vein 3-4 hour . You receive 111In-ibritumomab tiuxetan vein 30 minute . From Day -22 Day -16 , scan call whole-body planar scintigraphy image . In scan , special camera capture 2-dimensional image whole body see radioactive 111In- ibritumomab tiuxetan inject Day -22 spread . No additional radiation use scan . Scintigraphy perform right injection , 3-6 hour injection , 24 , 72 , 144 hour ( +/- 2 hour ) injection . After last scintigraphy image scan , scan review learn much radiation travel different organ decide much 90Y- ibritumomab use . On Day-14 , receive rituximab vein 3-4 hour . You receive calculate dose 90Y-ibritumomab tiuxetan vein 30 minute . On Days -5 , -4 , -3 , receive fludarabine bendamustine vein 1 hour day . On Days -3 Day 100 , stem cell cord blood , receive mycophenolate mofetil ( MMF ) vein mouth . MMF design block donor cell grow spread way could cause graft versus host disease ( GVHD -- condition transplant tissue attack recipient 's body ) . Starting Day -2 , stem cell relate match unrelated donor , receive tacrolimus vein continuous ( nonstop ) infusion able take mouth help prevent GVHD . You take tacrolimus mouth 2 time day 3 month . After , tacrolimus dose may lower GVHD . Your doctor discus . On Days -2 -1 , stem cell match unrelated donor cord blood , receive thymoglobulin ( ATG ) vein 4 hour . ATG design weaken immune system reduce risk reject transplant . On Day 0 , receive blood stem cell vein 30-45 minute . Blood ( less 1 teaspoon ) also draw measure much ( ) radiation 90Y- ibritumomab tiuxetan leave blood . Starting Day 0 , stem cell cord blood , receive filgrastim ( G-CSF ) needle skin 1 time day every day white blood count begin recover . G-CSF design help cell bone marrow divide , help raise white blood cell count quickly , low fever , decrease risk infection . On Days 1 , 3 , 6 , stem cell relate match unrelated donor , receive methotrexate 30 minute day vein help prevent GVHD . Patients receive match unrelated donor also give methotrexate Day 11 transplant . Starting Day 7 , stem cell relate match unrelated donor , receive G-CSF needle skin 1 time day every day white blood count begin recover . When doctor think need , also receive antibiotic antifungal drug help prevent and/or treat infection . Your doctor tell drug give possible side effect . You hospital 3-4 week receive stem cell transplant . During time , follow test procedure perform point doctor think need : - You physical exam , include measurement vital sign ( blood pressure , heart rate , temperature , breathe rate ) . - You ask feel side effect may . - Blood ( 4-6 teaspoon ) collect routine test , check kidney liver function , learn well transplant work . The following may also perform point doctor think need : - You may image scan check status disease and/or check possible infection . - You may bone marrow biopsy check status disease . To collect bone marrow biopsy , area hip site numb anesthetic , small amount bone marrow bone withdrawn needle . - You may transfusions blood and/or platelet . You must stay Houston area 100 day stem cell transplant . Long-Term Follow-Up : About 3 , 6 , 12 month stem cell transplant : - Blood ( 6 teaspoon ) collect routine test , check kidney liver function , see well transplant take . - You CT PET scan check status disease . - You bone marrow biopsy/aspirate check status disease . About 2 3 year stem cell transplant , receive phone call take less 10 minute learn . Length Study : You study 3 year . You may take study early disease get bad , intolerable side effect , unable follow study direction . You talk study doctor want leave study early . If take study early , still may need return routine post-transplant follow-up visit , transplant doctor decides need . It may life-threatening leave study begin receive study drug receive stem cell . This investigational study . Ibritumomab tiuxetan , rituximab , bendamustine , fludarabine FDA approve commercially available treatment lymphoma . The dose ibritumomab tiuxetan study design high FDA approve dose . The use ibritumomab tiuxetan bendamustine combination study drug stem cell transplant treatment lymphoma investigational . Up 20 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . 18 70 year age . 2 . Patients follow CD20+ lymphoid malignancy eligible allogeneic transplantation : a. Relapsed refractory follicular lymphoma ; b. Relapsed refractory high risk mantle cell lymphoma ( hi ki67 ; blastic ) ; c. Recurrent refractory marginal zone ; d. Recurrent refractory CLL/small lymphocytic lymphoma ; e. Doublehit lymphoma ; f. Diffuse large B cell lymphoma ; g. Richter 's patient ; h. Refractory recurrent Burkitts . 3 . Patients meet criterion # 2 follow eligible : . Less PR salvage chemotherapy ; b . Kinetic failure ; c. Having receive 3 line therapy ; d. Failure mobilize autologous stem cell ; e. 10 % marrow involvement ; f. 6 month post autologous stem cell transplant . 4 . Patients must fullymatched related donor match unrelated donor identify . Double cord ( least 4/6 match ) use adult match donor available . 5 . Performance score least 80 % Karnofsky 0 2 ECOG . 6 . Left ventricular EF &gt; /= 45 % uncontrolled arrythmias symptomatic heart disease . 7 . FEV1 , FVC &gt; /= 60 % correct DLCO &gt; /= 60 % . 8 . Serum creatinine &lt; /=1.6 mg/dL . Serum bilirubin &lt; 2 mg/dL ( unless due Gilbert 's Syndrome ) . 9 . SGPT &lt; 2 X upper limit normal . 10 . Men woman reproductive potential must agree follow accepted birth control method ( i.e. , hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , abstinence ) duration study . 11 . Negative Beta HCG test within 30 day woman child bear potential define postmenopausal 12 month previous surgical sterilization ) . Pregnancy test require postmenopausal surgically sterilize woman . 1 . Patient active CNS involvement lymphoid malignancy . 2 . Known infection HIV , HTLVI , Hepatitis B , Hepatitis C. 3 . Patients malignancy diagnose within 2 year prior study registration . Skin squamous basal cell carcinoma exception . 4 . Active bacterial , viral fungal infection . 5 . History stroke within 6 month prior study registration . 6 . A prior allogeneic stem cell transplant . 7 . Patient receive investigational drug within 3 week study registration . 8 . Presence circulate malignant lymphoid cell bone marrow lymphoma constitute 25 % cellular element . 9 . Serious nonmalignant malignant disease psychiatric illness , , opinion investigator would compromise protocol objective interfere participation . 10 . Patients breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic lymphocytic leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>CD20+ lymphoid malignancy</keyword>
	<keyword>Diffuse large B-cell lymphoma</keyword>
	<keyword>Allogeneic transplantation</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>In ibritumomab</keyword>
	<keyword>Y ibritumomab</keyword>
	<keyword>Zevalin</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Bendamustine Hydrochloride</keyword>
	<keyword>Bendamustine HCL</keyword>
	<keyword>CEP-18083</keyword>
	<keyword>SDX-105</keyword>
	<keyword>Treanda</keyword>
	<keyword>Stem Cell Transplantation</keyword>
	<keyword>Planar Scintigraphy</keyword>
	<keyword>Spect Scan</keyword>
	<keyword>Single Photon Emission-Computed Tomography</keyword>
	<keyword>CT Scan</keyword>
	<keyword>Computed Tomography</keyword>
	<keyword>G-CSF</keyword>
	<keyword>Filgrastim</keyword>
	<keyword>Neupogen</keyword>
	<keyword>Thymoglobulin</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Methotrexate</keyword>
	<keyword>Mycophenolate</keyword>
	<keyword>MMF</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>CellCept</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
</DOC>